Alder BioPharmaceuticals Inc. (Nasdaq: ALDR) initiated a PROMISE 2 clinical trial of its migraine prevention drug eptinezumab but the stock price tumbled $3.15 to close at $23.65.
Alder BioPharmaceuticals initiates new study
November 28, 2016 at 16:46 PM EST
